Topic Contents
Vitamin B3
Uses
Related Topics
The body uses the water-soluble vitamin B3 in the process of releasing energy from carbohydrates. It is needed to form fat from carbohydrates and to process alcohol. The niacin form of vitamin B3 also regulates cholesterol, though niacinamide does not.
What Are "Star" Ratings?
Reliable and relatively consistent scientific data showing a substantial health benefit.
Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.
For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support.
Our proprietary “Star-Rating” system was developed to help you easily understand the amount of scientific support behind each supplement in relation to a specific health condition. While there is no way to predict whether a vitamin, mineral, or herb will successfully treat or prevent associated health conditions, our unique ratings tell you how well these supplements are understood by the medical community, and whether studies have found them to be effective for other people.
For over a decade, our team has combed through thousands of research articles published in reputable journals. To help you make educated decisions, and to better understand controversial or confusing supplements, our medical experts have digested the science into these three easy-to-follow ratings. We hope this provides you with a helpful resource to make informed decisions towards your health and well-being.
This supplement has been used in connection with the following health conditions:
| Used for | Amount | Why |
|---|---|---|
|
High Cholesterol
|
1,500 to 3,000 mg daily under a doctor's supervision |
High amounts (several grams per day) of niacin, a form of vitamin B3, have been shown to lower cholesterol. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Osteoarthritis
|
Refer to label instructions |
Supplemental niacinamide (a form of vitamin B3) has been reported to increase joint mobility, improve muscle strength, and decrease fatigue in people with osteoarthritis.
|
|
||
| Used for | Amount | Why |
|---|---|---|
|
Dysmenorrhea
|
200 mg daily throughout menstrual cycle; for cramps: 100 mg every two to three hours |
The niacin form of vitamin B3 has been reported to be effective in relieving menstrual cramps in 87% of a group of women supplementing with it throughout the menstrual cycle. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Dysmenorrhea
(Rutin, Vitamin C) |
200 mg niacin daily, 300 mg vitamin C daily, and 60 mg rutin daily througout menstrual cycle; for cramps: 100 mg niacin every two to three hours |
Supplementing with a combination of vitamin B3, vitamin C, and the flavonoid rutin resulted in a 90% effectiveness for relieving menstrual cramps in one study. |
|
Peripheral Vascular Disease
|
1,200 mg a day of inositol hexaniacinate |
Vitamin B3 may help prevent and treat skin ulcers caused by peripheral vascular disease. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Raynaud’s Disease
|
3 to 4 grams daily of inositol hexaniacinate |
A variation on the B vitamin niacin, inositol hexaniacinate has been shown to reduce arterial spasm and improve peripheral circulation. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Schizophrenia
|
Consult a qualified healthcare practitioner |
High amounts of vitamin B3 may create a more optimal biochemical environment and increase recovery rate and reduce hospitalization and suicide rates. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Type 1 Diabetes
|
Consult a qualified healthcare practitioner |
Taking vitamin B3 (as niacin or niacinamide) might prevent or limit the severity of type 1 diabetes in your family. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Alcohol Withdrawal
|
Refer to label instructions |
Preliminary research has suggested that niacin may help wean some alcoholics away from alcohol. Niacinamide—a safer form of the same vitamin—might have similar actions. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Anxiety
|
Refer to label instructions |
Niacinamide (a form of vitamin B3) has been shown in animals to work in the brain in ways similar to anxiety medications. One study found that niacinamide helped people get through withdrawal from benzodiazepines—a common problem. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Cataracts
|
40 mg daily with 3 mg daily vitamin B2 |
Vitamin B3 is needed to protect glutathione, an important antioxidant in the eye. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Dermatitis Herpetiformis
(Tetracycline) |
Refer to label instructions |
Preliminary evidence indicates that, when drug therapy with dapsone is not tolerated, people may respond to a combination of tetracycline and nicotinamide (a form of vitamin B3). |
|
HIV and AIDS Support
|
Refer to label instructions |
Vitamin B3 may play a role in HIV prevention and treatment. A form of vitamin B3 (niacinamide) has been shown to inhibit HIV in test tube studies. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Hypoglycemia
|
Refer to label instructions |
Research has shown that supplementing with niacinamide (vitamin B3) can prevent blood sugar levels from falling excessively in people with hypoglycemia. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Hypothyroidism
|
Refer to label instructions |
Vitamin B3 (niacin) supplementation may decrease thyroid hormone levels. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Multiple Sclerosis
|
Refer to label instructions |
Thiamine (vitamin B1) deficiency may contribute to nerve damage. Researchers have found that injections of thiamine or thiamine combined with niacin (vitamin B3) may reduce symptoms. |
|
Photosensitivity
|
Refer to label instructions |
Niacinamide, a form of vitamin B3, can reduce the formation of a kynurenic acid—a substance that has been linked to photosensitivity. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Tardive Dyskinesia
|
Refer to label instructions |
In some studies, taking vitamin B3 as niacin or niacinamide, along with other nutrients, appeared to prevent the development of tardive dyskinesia. |
|
||
| Used for | Amount | Why |
|---|---|---|
|
Type 2 Diabetes
|
Refer to label instructions |
Small amounts of niacin (a form of vitamin B3) may help some people with type 2 diabetes. |
|
||
How It Works
How to Use It
In part because it is added to white flour, most people generally get enough vitamin B3 from their diets to prevent a deficiency. However, 10–25 mg of the vitamin can be taken as part of a B-complex or multivitamin supplement. Larger amounts are used for the treatment of various health conditions.
Where to Find It
The best food sources of vitamin B3 are peanuts, brewer’s yeast, fish, and meat. Some vitamin B3 is also found in whole grains.
Possible Deficiencies
Pellagra, the disease caused by a vitamin B3 deficiency, is rare in Western societies. Symptoms include loss of appetite, skin rash, diarrhea, mental changes, beefy tongue, and digestive and emotional disturbance.
Interactions
Interactions with Supplements, Foods, & Other Compounds
Vitamin B3 works with vitamin B1 and vitamin B2 to release energy from carbohydrates. Therefore, these vitamins are often taken together in a B-complex or multivitamin supplement (although most B3 research uses niacin or niacinamide alone).
Interactions with Medicines
Certain medicines interact with this supplement.
|
|
Some medicines may increase the need for this supplement. |
|---|---|
|
|
Some medicines interact with this supplement, so they should not be taken together. |
|
|
Some interactions between this supplement and certain medicines require more explanation. Click the link to see details. |
Note: The following list only includes the generic or class name of a medicine. To find a specific brand name, use the Medicines Index.
Side Effects
Side Effects
Niacinamide is almost always safe to take in amounts of 1,000 mg per day or less, though rare liver problems have occurred at amounts in excess of 1,000 mg per day. Niacin, in amounts as low as 50–100 mg, may cause flushing, headache, and stomachache in some people. Doctors sometimes prescribe very high amounts of niacin (as much as 3,000 mg per day or more) for certain health problems. These large amounts can cause liver damage, diabetes, gastritis, damage to eyes, and elevated blood levels of uric acid (which can cause gout). Symptoms caused by niacin supplements, such as flushing, have been reduced with sustained-release (also called ‘time-release’) niacin products. However, sustained-release forms of niacin have caused significant liver toxicity in some cases and, rarely, liver failure.71 , 72 , 73 , 74 , 75 One partial time-release (intermediate-release) niacin product has demonstrated clinical efficacy without flushing, and also with much less of the liver function abnormalities typically associated with sustained-release niacin formulations.76 However, this form of niacin is available by prescription only.
In a controlled clinical trial, 1,000 mg or more per day of niacin raised blood levels of homocysteine, a substance associated with increased risk of heart disease.77 Since other actions of niacin lower heart disease risk,78 , 79 the importance of this finding is unclear. Nonetheless, for all of the reasons discussed above, large amounts of niacin should never be taken without consulting a doctor.
The inositol hexaniacinate form of niacin has not been linked with the side effects associated with niacin supplementation. In a group of people being treated alternatively with niacin and inositol hexaniacinate for skin problems, niacin supplementation (50–100 mg per day) was associated with numerous side effects, including skin flushing, nausea, vomiting and agitation.80 In contrast, people taking inositol hexaniacinate experienced no complaints whatsoever, even at amounts two to five times higher than the previously used amounts of niacin. However, the amount of research studying the safety of inositol hexaniacinate remains quite limited. Therefore, people taking this supplement in large amounts (2,000 mg or more per day) should be under the care of a doctor.
References
1. Brown WV. Niacin for lipid disorders. Postgrad Med 1995;98:185–93 [review].
2. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000;160:1177–84.
3. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672–7.
4. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642–50.
5. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994;121:252–8.
6. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992;92:77–81 [review].
7. Knopp RH. Niacin and hepatic failure. Ann Intern Med 1989;111:769 [letter].
8. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100–5.
9. Kaufman W. The use of vitamin therapy for joint mobility. Therapeutic reversal of a common clinical manifestation of the ‘normal’ aging process. Conn State Med J 1953;17(7):584–9.
10. Kaufman W. The use of vitamin therapy to reverse certain concomitants of aging. J Am Geriatr Soc 1955;11:927.
11. Hoffer A. Treatment of arthritis by nicotinic acid and nicotinamide. Can Med Assoc J 1959;81:235–8.
12. Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res 1996;45:330–4.
13. Hudgins AP. Am Practice Digest Treat 1952;3:892–3.
14. Hudgins AP. Vitamins P, C and niacin for dysmenorrhea therapy. West J Surg 1954;Dec:610–1.
15. Mishima Y, Kamiya K, Sakaguchi S, et al. A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion. Angiology 1977;28:84–94.
16. Aylward M. Hexopal in Raynaud’s disease. J Int Med Res 1979;7:484–91.
17. Holti G. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud’s phenomenon. J Int Med Res 1979;7:473–83.
18. Ring EF, Bacon PA. Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud’s phenomenon. J Int Med Res 1977;5:217–22.
19. Hawkins DR, Bortin AW, Runyon RP. Orthomolecular psychiatry: niacin and megavitamin therapy. Psychosomatics 1970;11:517–21 [review].
20. Hawkins DR, Bortin AW, Runyon RP. Orthomolecular psychiatry: niacin and megavitamin therapy. Psychosomatics 1970;11:517–21 [review].
21. Autry JH. Workshop on orthomolecular treatment of schizophrenia: a report. Schizophr Bull 1975:94–103.
22. Petrie WM, Ban TA. Vitamins in psychiatry. Do they have a role? Drugs 1985;30:58–65 [review].
23. Hoffer A. Megavitamin B-3 therapy for schizophrenia. Can Psychiatr Assoc J 1971;16:499–504.
24. Wittenborn JR, Weber ES, Brown M. Niacin in the long-term treatment of schizophrenia. Arch Gen Psychiatry 1973;28:308–15.
25. Newbold HL, Mosher LR. Niacin and the schizophrenic patient. Am J Psychiatry 1970;127:535–6.
26. Petrie WM, Ban TA, Ananth JV. The use of nicotinic acid and pyridoxine in the treatment of schizophrenia. Int Pharmacopsychiatry 1981;16:245–50.
27. Ananth JV, Ban TA, Lehmann HE. Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics. Can Psychiatr Assoc J 1973;18:377–83.
28. Vaughan K, McConaghy N. Megavitamin and dietary treatment in schizophrenia: a randomised, controlled trial. Aust N Z J Psychiatry 1999;33:84–8.
29. Sandyk R, Pardeshi R. Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient. Int J Neurosci 1990;52:225–32.
30. Yamauchi M. Effects of L-dopa and vitamin B6 on electroencephalograms of schizophrenic patients: a preliminary report. Folia Psychiatr Neurol Jpn 1976;30:121–51.
31. Bucci L. Pyridoxine and schizophrenia. Br J Psychiatry 1973;122:240 [letter].
32. Molnar GD, Berge KG, Rosevear JW, et al. The effect of nicotinic acid in diabetes mellitus. Metabolism1964;13:181–9.
33. Gaut ZN, Pocelinko R, Solomon HM, Thomas GB. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration in nicotinic acid. Metabolism1971;20:1031–5.
34. Clearly JP. Vitamin B3 in the treatment of diabetes mellitus: case reports and review of the literature. J Nutr Med 1990;1:217–25.
35. Lewis CM, Canafax DM, Sprafka JM, Bazrbosa JJ. Double-blind randomized trail of nicotinamide on early-onset diabetes. Diabetes Care 1992;15:121–3.
36. Chase HP, Butler-Simon N, Garg S, et al. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia1990;33:444–6.
37. Mendola G, Casamitjana R, Gomis R. Effect of nicotinamide therapy upon B-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia1989;32:160–2.
38. Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset type 1. The nicotinamide trialists. Diabetes Care 1996;19:1357–63.
39. Vidal J, Fernandez-Balsells M, Sesmilo G, Aguilera E. Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care 2000;23:360–4.
40. Elliott RB, Picher CC, Fergusson DM, Stewart AW. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 1996;9:501–9.
41. Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study. An attempt to prevent type 1 diabetes. Diabetes1998;47:980–4.
42. Visalli N, Cavallo MG, Signore A, et al. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (The IMDIAB VI). Diabetes Metab Res Rev 1999;15:181–5.
43. Cleary JP. Etiology and biological treatment of alcohol addiction. J Neuro Ortho Med Surg 1985;6:75–7.
44. Smith RF. A five-year field trial of massive nicotinic acid therapy of alcoholics in Michigan. J Orthomolec Psychiatry 1974;3:327–31.
45. O’Halloren P. Pyridine nucleotides in the prevention, diagnosis and treatment of problem drinkers. West J Surg Obstet Gynecol 1961;69:101–4.
46. Eriksson CJP. Increase in hepatic NAD level—its effect on the redox state and on ethanol and acetaldehyde metabolism. Fed Eur Biochem Soc 1974;40:3117–20.
47. Replogle WH, Eicke FJ. Megavitamin therapy in the reduction of anxiety and depression among alcoholics. J Orthomolec Med 1988;4:221–4.
48. Mohler H, Polc P, Cumin R, et al. Niacinamide is a brain constituent with benzodiazepine-like actions. Nature 1979;278:563–5.
49. Vescovi PP, et al. Nicotinic acid effectiveness in the treatment of benzodiazepine withdrawal. Curr Ther Res 1987;41:1017.
50. Jacques PF, Chylack LT Jr. Epidemiologic evidence of a role for the antioxidant vitamins and carotenoids in cataract prevention. Am J Clin Nutr 1991;53:352S–5S.
51. Knekt P, Heliovaara M, Rissanen A, et al. Serum antioxidant vitamins and risk of cataract. BMJ 1992;305:1392–4.
52. Bhat KS. Nutritional status of thiamine, riboflavin and pyridoxine in cataract patients. Nutr Rep Internat 1987;36:685–92.
53. Prchal JT, Conrad ME, Skalka HW. Association of presenile cataracts with heterozygosity for galactosaemic states and with riboflavin deficiency. Lancet 1978; 1:12–3.
54. Sperduto RD, Hu TS, Milton RC, et al. The Linxian cataract studies. Arch Ophthalmol 1993;111:1246–53.
55. Murray MF. Niacin as a potential AIDS preventive factor. Med Hypotheses 1999;53:375–9.
56. Murray MF, Srinivasan A. Nicotinamide inhibits HIV-1 in both acute and chronic in vitro infection. Biochem Biophys Res Commun 1995;210:954–9.
57. Tang AM, Graham NMH, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency type 1 infection. Am J Epidemiol 1996;143:1244–56.
58. Graham NMH, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency type 1 infection. Am J Epidemiol 1996;143:1244–56.
59. Anderson RA et al. Chromium supplementation of humans with hypoglycemia. Fed Proc 1984;43:471.
60. Stebbing JB et al. Reactive hypoglycemia and magnesium. Magnesium Bull 1982;2:131–4.
61. Shansky A. Vitamin B3 in the alleviation of hypoglycemia. Drug Cosm Ind 1981;129(4):68–69,104–5.
62. Gaby AR, Wright JV. Nutritional regulation of blood glucose. J Advancement Med 1991;4:57–71.
63. Shakir KMM, Kroll S, Aprill BS, et al. Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state. Mayo Clin Proc 1995;70:556–8.
64. O’Brien T, Silverberg JD, Nguyen TT. Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-binding globulin. Mayo Clin Proc 1992;67:465–8.
65. Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: a pilot study. Br J Dermatol 1986;115:77–80.
66. Tkacz C. A preventive measure for tardive dyskinesia. J Int Acad Prev Med 1984;8:(5)5–8.
67. Toll N. To the editor. J Orthomolec Psychiatry 1982;11:42.
68. Molnar GD, Berge KG, Rosevear JW, et al. The effect of nicotinic acid in diabetes mellitus. Metabolism 1964;13:181–9.
69. Gaut ZN, Pocelinko R, Solomon HM, Thomas GB. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration in nicotinic acid. Metabolism 1971;20:1031–5.
70. Clearly JP. The importance of oxidant injury as a cause of impaired mitochondrial oxidation in diabetes. J Orthomolec Med 1988;3:164–74.
71. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained—vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672–7.
72. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642–50.
73. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994;121:252–8.
74. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992;92:77–81 [Review].
75. Knopp RH. Niacin and hepatic failure. Ann Intern Med 1989;111:769 [letter].
76. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100–5.
77. Garg R, Malinow M, Pettinger M, Upson B, Hunninghake D. Niacin treatment increases plasma homocyst(e)ine levels. Am Heart J 1999;138:1082–7.
78. Brown WV. Niacin for lipid disorders. Postgrad Med 1995;98:185–93 [review].
79. Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol 1998;82(12A):18U–23U [review].
80. Welsh AL, Ede M. Inositol hexanicotinate for improved nicotinic acid therapy. Int Record Med 1961;174:9–15.
Last Review: 08-17-2011
Copyright © 2011 Aisle7. All rights reserved. www.Aisle7.net
Learn more about Aisle7, the company.
The information presented in Aisle7 is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires June 2013.
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
